Goldman Sachs has restarted coverage on CG Oncology (CGON, Financial), assigning it a Buy rating accompanied by a price target of $40. The firm expressed confidence in the competitive position of cretostimogene, particularly when compared to TAR-200. This optimistic stance reflects Goldman Sachs' belief in the potential of CG Oncology's clinical advancements to perform well in the market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for CG Oncology Inc (CGON, Financial) is $62.75 with a high estimate of $82.00 and a low estimate of $23.00. The average target implies an upside of 132.06% from the current price of $27.04. More detailed estimate data can be found on the CG Oncology Inc (CGON) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, CG Oncology Inc's (CGON, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
